Financial Performance - The company's revenue for Q3 2022 was ¥130,983,535.64, a decrease of 26.52% compared to the same period last year[6]. - The net profit attributable to shareholders was ¥83,705,363.76, down 26.39% year-on-year[6]. - The net profit excluding non-recurring gains and losses was ¥41,058,539.50, reflecting a significant decline of 58.31% compared to the previous year[6]. - The company's basic earnings per share were ¥0.6479, down 67.71% year-on-year[6]. - In the first three quarters of 2022, the company achieved operating revenue of 430 million RMB, a year-on-year decrease of 47.07%[27]. - In Q3 2022, the company achieved revenue of 131 million yuan, a year-over-year decrease of 26.52%, but a quarter-over-quarter increase of 6.10%[28]. - Revenue from non-COVID-19 related business was 111 million yuan, showing a year-over-year growth of 18.06% and a quarter-over-quarter growth of 13.20%[28]. - Total operating revenue for the current period is CNY 430,286,790.03, a decrease from CNY 812,948,531.27 in the previous period, representing a decline of approximately 47%[40]. - Net profit for the current period is CNY 275,901,898.54, down from CNY 556,362,582.99 in the previous period, indicating a decrease of approximately 51%[43]. - Operating profit decreased to CNY 322,168,393.07 from CNY 658,413,618.40, reflecting a decline of around 51%[43]. - The basic earnings per share for the current period is CNY 2.5359, compared to CNY 10.5195 in the previous period, a decline of approximately 76%[43]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,511,465,199.82, a decrease of 5.50% from the end of the previous year[6]. - As of September 30, 2022, the company's total assets amounted to 6.51 billion yuan, down from 6.89 billion yuan at the beginning of the year[33]. - The company's cash and cash equivalents were approximately 2.37 billion yuan, a decrease from 2.87 billion yuan at the start of the year[33]. - The total liabilities of the company as of September 30, 2022, were 170.83 million yuan, compared to 137.92 million yuan at the beginning of the year[36]. - The company's total equity attributable to shareholders was approximately 6.34 billion yuan, down from 6.75 billion yuan at the beginning of the year[39]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥169,882,187.35, a decrease of 62.73% compared to the same period last year[14]. - Operating cash inflow totaled ¥502,400,622.79, a decrease of 42.4% from ¥872,847,387.20 in the previous period[47]. - Net cash outflow from operating activities was ¥169,882,187.35, down from ¥455,852,218.88, indicating a significant decline[47]. - Cash inflow from investment activities was ¥10,639,688,833.56, compared to ¥2,545,611,806.61 in the prior period, showing a substantial increase[50]. - Cash outflow from financing activities amounted to ¥693,261,769.57, while the previous period recorded inflow of ¥4,720,050,530.28, indicating a shift in financing strategy[50]. - The ending balance of cash and cash equivalents was ¥2,325,314,658.30, down from ¥4,654,977,849.90, indicating a liquidity contraction[50]. Inventory and Fixed Assets - Inventory increased by 67.27% to ¥41,401,459.95, primarily due to increased raw material reserves[11]. - Fixed assets rose by 75.98% to ¥104,549,193.03, mainly due to the purchase of production and R&D equipment[11]. - The company reported an increase in inventory to approximately 41.40 million yuan, up from 24.75 million yuan at the beginning of the year[33]. Research and Development - The company maintained its position as a mainstream supplier of COVID-19 related biological reagents, leveraging its extensive R&D experience in the field[27]. - The company increased its R&D investment in non-COVID-19 related business, resulting in a 30.52% year-on-year increase in CRO service revenue, totaling 76.81 million RMB[27]. - The company’s strategic focus on enhancing long-term competitiveness through increased R&D investment in non-COVID-19 related business is evident[27]. - Research and development expenses for the current period are CNY 39,332,093.12, up from CNY 32,116,971.18, indicating an increase of approximately 22%[40]. Government Support and Other Income - The company received government subsidies amounting to ¥13,363,773.64 during the reporting period[9]. - Other income increased to CNY 13,924,074.09 from CNY 3,353,594.12, reflecting a growth of about 316%[40]. - The company reported a tax expense of CNY 46,290,442.18, down from CNY 101,551,035.41, indicating a decrease of approximately 54%[43]. Subsidiary Developments - The Suzhou subsidiary has completed renovation acceptance and is currently in the laboratory equipment debugging phase[32]. - The Taizhou subsidiary has completed the main renovation work of the first phase of the laboratory and has begun trial operations[32]. - The company has ongoing projects in Suzhou and Taizhou, indicating a focus on market expansion and new technology development[32].
义翘神州(301047) - 2022 Q3 - 季度财报